High drug prices frustrate government-sponsored health programs; report

1 March 2017

Health plans partnering with Express Scripts are delivering high-quality, affordable pharmacy care to millions of individuals enrolled in government-sponsored programs, but this record is at risk without decisive action to advance additional pro-patient and pro-payer policy changes, according to new research released today by Express Scripts (Nasdaq: ESRX), the largest pharmacy benefit management organization in the USA.

"Our country is engaged in an important dialogue about how best to provide millions of Americans with much needed pharmacy care, and how to deliver that care in the most affordable and sustainable way," said Glen Stettin, chief innovation officer at Express Scripts. "While the health plans entrusted with implementing these programs are, overall, managing pharmacy costs effectively, Express Scripts has identified additional areas where policymakers should act now to curb high drug prices and reduce wasteful spending," Dr Stettin added.

Top-line findings

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK